Prognostic Impact of the MDM2(SNP309) Allele in Leukemia and Lymphoma

A T-to-G germline single nucleotide polymorphism in the promoter region of MDM2 (SNP309) has been reported to markedly accelerate tumor formation in humans suggesting that it may represent a powerful cancer predisposing allele. Since its first description in 2004, a large number of retrospective ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Post, Sean M., Pant, Vinod, Abbas, Hussein, Quintás-Cardama, Alfonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2010
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3157715/
https://www.ncbi.nlm.nih.gov/pubmed/21301048
Descripción
Sumario:A T-to-G germline single nucleotide polymorphism in the promoter region of MDM2 (SNP309) has been reported to markedly accelerate tumor formation in humans suggesting that it may represent a powerful cancer predisposing allele. Since its first description in 2004, a large number of retrospective analyses involving a wide variety of human malignancies have been reported, showing conflicting results regarding the impact of Mdm2(SNP309) status on cancer risk and response to cancer therapy. Here, we appraise the available information on the effect of Mdm2(SNP309) in lymphoma and leukemia and discuss the factors that likely account for the conflicting results observed in the studies reported to date.

Ejemplares similares